The Cooper Companies, Inc. (COO) reported a market capitalization of $13.94 billion, experiencing a share decline of 12.7% in 2023, compared to a 2% decrease in the industry and a 4.1% fall in the S&P 500. While the company is projected to grow its bottom line by 8.4% over the next five years, it faces challenges from channel volatility, a shift to private-label products, Asia-Pacific weakness, and geopolitical risks impacting its fertility segment.
CooperVision, COO’s optical division, has gained market share for 18 consecutive years, driven by premium products like the MyDay lens portfolio, which saw growth above 15%. The company’s operating margins reached 26.9% due to operational efficiencies, while CooperSurgical is on a recovery path, fueled by increasing IVF cycles in the U.S. and Europe. However, ongoing weakness in the Japanese market poses a near-term headwind for growth.
The Zacks Consensus Estimate for COO’s fiscal year 2026 revenues is $4.32 billion, reflecting a 5.5% increase from the previous year, alongside an expected adjusted EPS growth of 11.7% to $4.60. The company’s earnings have surpassed estimates in the past four quarters, yielding an average surprise of 4.11%.
